Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon Provigil Focus: Studying ADHD In Children, Filing Shift Work sNDA

Executive Summary

Cephalon plans to meet with FDA to discuss clinical requirements for a Provigil attention deficit hyperactivity disorder indication following positive results from a Phase II pediatric study, CEO Frank Baldino, PhD, said
Advertisement

Related Content

Cephalon Launches Provigil Label Expansion; DTC Campaign Possible
Cephalon Launches Provigil Label Expansion; DTC Campaign Possible
Cephalon Actiq Extensions Start In 2005, Provigil Isomer On Market In 2006
Cephalon Actiq Extensions Start In 2005, Provigil Isomer On Market In 2006
Cephalon Provigil ADHD Trial Failure Cuts Anesta Merger Value By One-Third
Cephalon Provigil ADHD Trial Failure Cuts Anesta Merger Value By One-Third
Advertisement
UsernamePublicRestriction

Register

PS040757

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel